Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
Jingping Zhao,1,* Lehua Li,1,* Jianguo Shi,2 Yi Li,3 Xiufeng Xu,4 Keqing Li,5 Lili Zhang,6 Shangli Cai,6 Yu Feng,6 Jianmin Zhuo,6 Weihong Liu,6 Huafei Lu6 1Department of Psychiatry, The Mental Health Institute, The Second Xiangya Hospital of Central South University, 2Department of Psychiatry, Ment...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ac0abe1e64ef439d9f5f5b6cc0709df6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ac0abe1e64ef439d9f5f5b6cc0709df6 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ac0abe1e64ef439d9f5f5b6cc0709df62021-12-02T03:30:30ZSafety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study1178-2021https://doaj.org/article/ac0abe1e64ef439d9f5f5b6cc0709df62017-08-01T00:00:00Zhttps://www.dovepress.com/safety-and-efficacy-of-paliperidone-palmitate-1-month-formulation-in-c-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Jingping Zhao,1,* Lehua Li,1,* Jianguo Shi,2 Yi Li,3 Xiufeng Xu,4 Keqing Li,5 Lili Zhang,6 Shangli Cai,6 Yu Feng,6 Jianmin Zhuo,6 Weihong Liu,6 Huafei Lu6 1Department of Psychiatry, The Mental Health Institute, The Second Xiangya Hospital of Central South University, 2Department of Psychiatry, Mental Health Center of Xi’an City, 3Department of Psychiatry, Mental Health Center of Wuhan City, 4Department of Psychiatry, First Affiliated Hospital of Kunming Medical University, 5Department of Psychiatry, The Sixth People’s Hospital of Hebei Province, 6Department of Medical Affairs, Xi’an Janssen Pharmaceutical Ltd., Beijing, People’s Republic of China *These authors contributed equally to this work Rationale: Long-acting injectable (LAI) paliperidone palmitate 1-month formulation (PP1M) has demonstrated acceptable tolerability and favorable clinical outcomes in Western and Asian patients with schizophrenia. Hence, analysis of the outcomes of long-term PP1M treatment specifically in Chinese patients is of interest.Objective: The aim of this study is to evaluate the long-term safety and efficacy of PP1M treatment in Chinese patients with schizophrenia.Methods: In this 25-week, open-label, Phase IV study, patients (18–65 years) diagnosed with schizophrenia and having a baseline Positive and Negative Syndrome Scale (PANSS) total score of 60–120 (inclusive) were enrolled. All patients received injections of PP1M 150 mg eq. (day 1) and 100 mg eq. (day 8), followed by a flexible once-monthly maintenance dosing (75, 100, or 150 mg eq.).Results: Of the 353 patients, 234 (66.3%) completed the study treatment (mean age, 31.1 years; 52.7% men). The PANSS total score (primary end point) improved significantly over the 6-month treatment period (mean [standard deviation] change from baseline to end of treatment, -27.2 [18.30]; P<0.0001). The Clinical Global Impressions-Severity and Personal and Social Performance scores (secondary end points) also improved significantly (P<0.0001). At 6 months, PP1M had a positive impact on medication satisfaction, adherence, and increased preference for LAIs. Treatment-emergent adverse events (TEAEs) were reported by 181 (51.3%) patients (TEAEs ≥5%: extrapyramidal disorder [15.3%], akathisia [10.5%], blood prolactin increase [8.8%], insomnia [5.4%]). A total of 8 deaths were reported, including 4 completed suicides.Conclusion: Long-term treatment with PP1M was efficacious, and no new safety concerns were identified in Chinese patients with schizophrenia. Overall, the results were comparable with observations from previous studies. Keywords: Chinese, long-acting injectables, open-label, paliperidone palmitate, PANSS, schizophrenia Zhao JPLi LHShi JGLi YXu XFLi KQZhang LLCai SLFeng YZhuo JMLiu WHLu HFDove Medical PressarticleChineselong-acting injectablesopen-labelpaliperidone palmitatePANSSschizophreniaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 2045-2056 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Chinese long-acting injectables open-label paliperidone palmitate PANSS schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Chinese long-acting injectables open-label paliperidone palmitate PANSS schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Zhao JP Li LH Shi JG Li Y Xu XF Li KQ Zhang LL Cai SL Feng Y Zhuo JM Liu WH Lu HF Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study |
| description |
Jingping Zhao,1,* Lehua Li,1,* Jianguo Shi,2 Yi Li,3 Xiufeng Xu,4 Keqing Li,5 Lili Zhang,6 Shangli Cai,6 Yu Feng,6 Jianmin Zhuo,6 Weihong Liu,6 Huafei Lu6 1Department of Psychiatry, The Mental Health Institute, The Second Xiangya Hospital of Central South University, 2Department of Psychiatry, Mental Health Center of Xi’an City, 3Department of Psychiatry, Mental Health Center of Wuhan City, 4Department of Psychiatry, First Affiliated Hospital of Kunming Medical University, 5Department of Psychiatry, The Sixth People’s Hospital of Hebei Province, 6Department of Medical Affairs, Xi’an Janssen Pharmaceutical Ltd., Beijing, People’s Republic of China *These authors contributed equally to this work Rationale: Long-acting injectable (LAI) paliperidone palmitate 1-month formulation (PP1M) has demonstrated acceptable tolerability and favorable clinical outcomes in Western and Asian patients with schizophrenia. Hence, analysis of the outcomes of long-term PP1M treatment specifically in Chinese patients is of interest.Objective: The aim of this study is to evaluate the long-term safety and efficacy of PP1M treatment in Chinese patients with schizophrenia.Methods: In this 25-week, open-label, Phase IV study, patients (18–65 years) diagnosed with schizophrenia and having a baseline Positive and Negative Syndrome Scale (PANSS) total score of 60–120 (inclusive) were enrolled. All patients received injections of PP1M 150 mg eq. (day 1) and 100 mg eq. (day 8), followed by a flexible once-monthly maintenance dosing (75, 100, or 150 mg eq.).Results: Of the 353 patients, 234 (66.3%) completed the study treatment (mean age, 31.1 years; 52.7% men). The PANSS total score (primary end point) improved significantly over the 6-month treatment period (mean [standard deviation] change from baseline to end of treatment, -27.2 [18.30]; P<0.0001). The Clinical Global Impressions-Severity and Personal and Social Performance scores (secondary end points) also improved significantly (P<0.0001). At 6 months, PP1M had a positive impact on medication satisfaction, adherence, and increased preference for LAIs. Treatment-emergent adverse events (TEAEs) were reported by 181 (51.3%) patients (TEAEs ≥5%: extrapyramidal disorder [15.3%], akathisia [10.5%], blood prolactin increase [8.8%], insomnia [5.4%]). A total of 8 deaths were reported, including 4 completed suicides.Conclusion: Long-term treatment with PP1M was efficacious, and no new safety concerns were identified in Chinese patients with schizophrenia. Overall, the results were comparable with observations from previous studies. Keywords: Chinese, long-acting injectables, open-label, paliperidone palmitate, PANSS, schizophrenia |
| format |
article |
| author |
Zhao JP Li LH Shi JG Li Y Xu XF Li KQ Zhang LL Cai SL Feng Y Zhuo JM Liu WH Lu HF |
| author_facet |
Zhao JP Li LH Shi JG Li Y Xu XF Li KQ Zhang LL Cai SL Feng Y Zhuo JM Liu WH Lu HF |
| author_sort |
Zhao JP |
| title |
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study |
| title_short |
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study |
| title_full |
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study |
| title_fullStr |
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study |
| title_full_unstemmed |
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study |
| title_sort |
safety and efficacy of paliperidone palmitate 1-month formulation in chinese patients with schizophrenia: a 25-week, open-label, multicenter, phase iv study |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/ac0abe1e64ef439d9f5f5b6cc0709df6 |
| work_keys_str_mv |
AT zhaojp safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT lilh safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT shijg safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT liy safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT xuxf safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT likq safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT zhangll safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT caisl safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT fengy safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT zhuojm safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT liuwh safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy AT luhf safetyandefficacyofpaliperidonepalmitate1monthformulationinchinesepatientswithschizophreniaa25weekopenlabelmulticenterphaseivstudy |
| _version_ |
1718401751101472768 |